Copied
 
 
2023, EUR
06.06.2024
Bruttoresultat

-5.000

Primær drift

73.273'

Årets resultat

10.693'

Aktiver

140''

Kortfristede aktiver

125'

Egenkapital

140''

Afkastningsgrad

52 %

Soliditetsgrad

100 %

Likviditetsgrad

87 %

Resultat
06.06.2024
Årsrapport
2023
06.06.2024
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Nettoomsætning1.569.240.0001.513.706.0001.417.811.0000981.554.000
Bruttoresultat-5.000-4.000-5.00000
Resultat af primær drift73.273.00059.267.00054.495.000-2.000-2.000
Indtægter af kapitalandele (tilknyttede og associerede) 00000
Finansielle indtægter10.974.0006.267.00012.317.00000
Finansieringsomkostninger000-1.0000
Andre finansielle omkostninger-2.000-4.000-2.00000
Resultat før skat10.691.00012.274.00018.514.00015.002.00019.005.000
Resultat10.693.00012.276.00018.515.00015.003.00019.005.000
Forslag til udbytte-3.300.0000-2.750.000-2.750.000-8.360.000
Aktiver
06.06.2024
Årsrapport
2023
06.06.2024
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Kortfristede varebeholdninger358.303.000309.607.000271.226.00000
Kortfristede tilgodehavender fra salg og tjenesteydelser 2.0002.0002.0001.0000
Likvider123.0001.0004.985.0001.0000
Kortfristede aktiver125.0003.0002.0002.0000
Immaterielle aktiver og goodwill495.065.000518.591.000541.329.00000
Finansielle anlægsaktiver139.766.000130.938.000123.049.000106.239.00098.554.000
Materielle aktiver135.910.000123.101.000109.757.00000
Langfristede aktiver139.766.000130.938.000123.049.000106.239.00098.554.000
Aktiver139.891.000130.941.000123.051.000106.241.00098.554.000
Aktiver
06.06.2024
Passiver
06.06.2024
Årsrapport
2023
06.06.2024
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Forslag til udbytte3.300.00002.750.0002.750.0008.360.000
Egenkapital139.747.000130.924.000123.041.000106.236.00098.552.000
Hensatte forpligtelser43.883.00037.347.00068.151.00000
Langfristet gæld til banker556.612.000560.103.000550.240.00000
Anden langfristet gæld0000
Leverandører af varer og tjenesteydelser90.457.00086.860.000116.466.00000
Kortfristede forpligtelser144.00017.00010.0005.0002.000
Gældsforpligtelser144.00017.00010.0005.0002.000
Forpligtelser144.00017.00010.0005.0002.000
Passiver139.891.000130.941.000123.051.000106.241.00098.554.000
Passiver
06.06.2024
Nøgletal
06.06.2024
Årsrapport
2023
06.06.2024
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Afkastningsgrad 52,4 %45,3 %44,3 %0,0 %0,0 %
Dækningsgrad 0,0 %0,0 %0,0 %Na.Na.
Resultatgrad 0,7 %0,8 %1,3 %Na.1,9 %
Varelagerets omsætningshastighed 4,4 4,9 5,2 Na.Na.
Egenkapitals-forretning 7,7 %9,4 %15,0 %14,1 %19,3 %
Payout-ratio 30,9 %Na.14,9 %18,3 %44,0 %
Gældsdæknings-nøgletal Na.Na.Na.-200,0 %Na.
Soliditestgrad 99,9 %100,0 %100,0 %100,0 %100,0 %
Likviditetsgrad 86,8 %17,6 %20,0 %40,0 %Na.
Resultat
06.06.2024
Gæld
06.06.2024
Årsrapport
06.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 06.06.2024)
Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act ​governing reporting class C enterprises (large). The accounting policies applied to these consolidated financial statements and parent financial statements are consistent with those applied last year. The annual report is presented in EUR.
Oplysning om pantsætninger og sikkerhedsstillelser:21 Assets charged and collateralThe Group has a fixed charge over inventories of EUR 25.0 million as security for bank debt and debt to credit institutions. In addition, pledged unlisted shares in certain Group companies with a total carrying amount of EUR 498.2 million at 31 December 2023 have been provided as security for bank debt and debt to credit institutions. Mortgage deeds and letter of indemnity have been issued as security for credit institutions with a nominal amount of EUR 64.9 million. The actual liability on the balance sheet date amounts to EUR 28.6 million and the carrying amount of plegded properties amounts to EUR 64.6 million at 31 December 2023.
Beretning
06.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-06-05
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Executive Board has today considered and approved the annual report of HBS Capital ApS for the financial year 01. 01. 2023 - 31. 12. 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesHBS Capital ApS is a holding company established and ultimately owned by the Bøgh-Sørensen family. The Group’s primary business activity is being an ambitious operator in the European market for pharmaceuticals through the investment in Orifarm Group A/S, which is the largest supplier of parallel imported pharmaceuticals in Europe, and a producer and seller of well-known brands as well as generic pharmaceuticals. Secondly the HBS Capital Group invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private, through the ownership of Habico Invest A/S. Orifarm Group Orifarm Group is a dynamic international player in the healthcare business. Our vision is to be no. 1 in making healthcare a better deal. Every day, we strive to make high quality pharmaceuticals at affordable prices available to end users by manufacturing, commercializing, and trading products. The Group's purpose is to provide as many people as possible with access to affordable quality medicine. We supply a wide range of high-quality pharmaceuticals across several therapeutic areas and stages of illness. Our portfolio covers pharmaceuticals for primary as well as secondary care by specialists, over the counter (OTC), and consumer healthcare products. It is our mission to challenge the market and make affordable, high-quality healthcare accessible. We want to create competition and provide important savings for society and to ensure better value for money for consumers while maintaining a high quality in our products. Orifarm Group operates on three product platforms: Pharma Trade Import, re-packaging and sales of medicine leveraging price arbitrages between countries; including medicines without an MA in a country (unlicensed) and comparator drugs for clinical trials. Specialty Rx Off-patent, small molecule medicine sold via pharmacy substitution and hospital tendering (nGx) or prescribed by physicians without substitution (pRx). Consumer Healthcare Products for health needs available without prescription; chosen by consumers; OTC regulated as pharmaceutical with an API, while VMS is regulated as food supplements (no API). Habico Invest Habico Invest A/S invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK